The AP3B1 gene plays a critical role in the development of Hermansky-Pudlak syndrome type 2 (HPS2), a rare genetic disorder characterized by albinism, bleeding disorders, and pulmonary and intestinal complications. The genetic test for HPS2 through the analysis of the AP3B1 gene is a pivotal step in diagnosing this condition, enabling healthcare professionals to devise appropriate management and treatment strategies for affected individuals.
Conducted at DNA Labs UAE, the test scrutinizes the AP3B1 gene for mutations that lead to HPS2. This comprehensive genetic testing ensures a precise diagnosis, facilitating early intervention and tailored care plans for patients. The cost of the test is set at 4400 AED, reflecting the intricate processes and advanced technology utilized in identifying the genetic alterations associated with this syndrome.
By opting for this genetic test, individuals suspected of having HPS2 or families with a history of the syndrome can gain valuable insights into their genetic makeup, paving the way for informed healthcare decisions and potentially mitigating the impact of the syndrome's symptoms. DNA Labs UAE, with its state-of-the-art facilities and expertise in genetic diagnostics, stands at the forefront of genetic testing services, offering hope and clarity to those affected by Hermansky-Pudlak syndrome type 2.
The Hermansky-Pudlak Syndrome type 3 (HPS3) genetic test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify mutations in the HPS3 gene. This gene is crucial for the proper formation of lysosomes and related organelles in cells, and mutations can lead to Hermansky-Pudlak syndrome (HPS), a rare autosomal recessive disorder. HPS is characterized by a lack of pigment in the skin, hair, and eyes (albinism), a propensity for bleeding due to platelet abnormalities, and in some cases, lung and bowel diseases. Identifying mutations in the HPS3 gene through this test can provide definitive diagnosis of HPS type 3, enabling targeted management and treatment strategies for affected individuals. The cost of the HPS3 gene test at DNA Labs UAE is 4400 AED, reflecting the specialized nature of this genetic analysis and its significance in providing critical health information.
The "DHH Gene 46XY Gonadal Dysgenesis Partial with Minifascicular Neuropathy Genetic Test" is a specialized diagnostic tool offered by DNA Labs UAE, aimed at detecting mutations in the DHH gene that are associated with 46XY gonadal dysgenesis partial syndrome accompanied by minifascicular neuropathy. This condition is characterized by underdeveloped gonads in individuals who are genetically male (with one X and one Y chromosome), leading to a range of developmental and reproductive issues. Additionally, the presence of minifascicular neuropathy indicates a neurological component, where nerve fibers are abnormally organized into small bundles or fascicles, potentially causing sensory and motor deficits.
The test is critical for early diagnosis and management of the condition, enabling healthcare providers to offer appropriate treatments and interventions to improve the quality of life of affected individuals. The cost of the test is set at 4400 AED, reflecting the specialized nature of the genetic analysis and the comprehensive insights it provides into the patient's condition. By conducting this test at DNA Labs UAE, patients and their families can access advanced genetic testing services within the region, supported by a team of experts in genetics and molecular diagnostics.
The CACNA1F Gene Cone-rod dystrophy X-linked type 3 Genetic Test is a specialized diagnostic examination aimed at identifying mutations in the CACNA1F gene, which are associated with Cone-rod dystrophy X-linked type 3, a rare genetic disorder. This condition primarily affects the eyes, leading to a progressive loss of vision due to the deterioration of cone and rod cells in the retina. The test is crucial for early diagnosis, allowing for appropriate management and counseling for affected individuals and their families.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed for specific genetic alterations in the CACNA1F gene. The results can provide invaluable information for affected individuals, including insights into the progression of the disease, potential treatments, and the risk of passing the condition on to offspring.
The cost of the CACNA1F Gene Cone-rod dystrophy X-linked type 3 Genetic Test is set at 4400 AED, reflecting the sophisticated technology and expert analysis required to accurately identify mutations in the CACNA1F gene. While the price may seem high, the information gained from this test can be critical for the effective management of Cone-rod dystrophy X-linked type 3, significantly impacting the quality of life for those diagnosed with this challenging condition.
The TGFBI Gene Corneal Dystrophy Epithelial Basement Membrane Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the TGFBI gene that are associated with various types of corneal dystrophies, including epithelial basement membrane dystrophy (EBMD). EBMD, also known as map-dot-fingerprint dystrophy, is a common eye condition that can lead to vision impairment due to irregularities in the cornea's epithelial basement membrane. The test plays a crucial role in the accurate diagnosis and management of patients affected by or at risk of developing this condition.
By analyzing the patient's DNA, the test can pinpoint specific genetic mutations in the TGFBI gene, offering valuable insights into the disease's prognosis, potential treatment strategies, and the risk of inheritance for family members. The cost of the test is 4400 AED, reflecting the advanced technology and expertise required to conduct this sophisticated genetic analysis. Conducted at DNA Labs UAE, a leading facility in genetic testing, this service ensures high accuracy and reliability, providing essential information for patients and healthcare providers in managing corneal dystrophies effectively.
The VSX1 gene test for Corneal Dystrophy, Posterior Polymorphous Type 1 (PPCD1), is a specialized genetic analysis offered by DNA Labs UAE. This test is designed to identify mutations in the VSX1 gene, which have been associated with PPCD1, a rare genetic disorder affecting the cornea. PPCD1 is characterized by changes in the endothelial cells lining the back of the cornea, leading to corneal edema, blisters on the cornea, and vision problems. The VSX1 gene test is crucial for diagnosing the condition, understanding its genetic basis, and guiding treatment decisions.
The cost of the VSX1 gene test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect any genetic abnormalities in the VSX1 gene that may lead to PPCD1. By opting for this test, patients and their families can gain valuable insights into the genetic underpinnings of the condition, enabling informed decisions about management and potential interventions to preserve vision and improve quality of life.
The SLC4A11 Gene Corneal Endothelial Dystrophy Type 2 Genetic Test is a specialized diagnostic examination offered by DNA Labs UAE, aimed at detecting mutations in the SLC4A11 gene, which are associated with the development of Corneal Endothelial Dystrophy Type 2 (CHED2). This condition is a rare, inherited eye disorder that primarily affects the endothelium, the innermost layer of the cornea, leading to swelling, blurred vision, and potentially severe visual impairment.
The test is crucial for individuals with a family history of CHED2 or those exhibiting symptoms, as early detection can facilitate timely management and treatment options to preserve vision. Conducted through a blood sample or buccal swab, the test specifically looks for genetic abnormalities in the SLC4A11 gene, which plays a significant role in maintaining corneal transparency and hydration.
Priced at 4400 AED, the genetic test at DNA Labs UAE is performed with high precision and accuracy, providing individuals and their healthcare providers with vital information for making informed decisions regarding the condition's management and treatment. The test not only aids in the diagnosis but also helps in understanding the risk of passing the condition to future generations, thereby playing a significant role in family planning and genetic counseling.
The "NLRP1 Gene Corneal Intraepithelial Dyskeratosis and Ectodermal Dysplasia Genetic Test" is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the NLRP1 gene, which are linked to corneal intraepithelial dyskeratosis and ectodermal dysplasia. These conditions are part of a group of disorders that affect the skin, hair, nails, and occasionally the teeth and sweat glands, often leading to symptoms from birth or early childhood. Corneal intraepithelial dyskeratosis specifically impacts the eyes, leading to vision problems due to abnormal growth of the cornea.
The test, priced at 4400 AED, utilizes advanced genetic sequencing techniques to analyze the NLRP1 gene, aiming to provide accurate diagnosis and insights. This information is crucial for understanding the risk of passing the condition to offspring, planning treatments, and managing symptoms effectively. Conducted at DNA Labs UAE, a facility known for its state-of-the-art technology and expertise in genetic diagnostics, this test represents a significant step forward in personalized medicine and genetic understanding of complex dermatological and ocular conditions.
The PXDN gene plays a crucial role in ocular development and function. Mutations in this gene have been linked to corneal opacification and various other ocular anomalies, which can impact vision quality and lead to significant visual impairment. To identify mutations in the PXDN gene that may contribute to these conditions, DNA Labs UAE offers a specialized genetic test.
This genetic test involves analyzing the patient's DNA to detect any abnormalities or mutations in the PXDN gene that could be responsible for the development of corneal opacification and other related ocular anomalies. Early detection through this test can be crucial for the management and treatment of these conditions, offering a chance to mitigate the progression of symptoms and improve the patient's quality of life.
The test is priced at 4400 AED and is conducted in DNA Labs UAE's state-of-the-art facilities. The lab employs cutting-edge technology and adheres to the highest standards of accuracy and reliability in genetic testing. Upon completion, a comprehensive report is provided, detailing the findings and, if applicable, recommendations for follow-up care or interventions. This test is an invaluable tool for individuals at risk of PXDN gene-related ocular conditions, enabling proactive healthcare decisions.
The EFEMP1 gene test for Doyne honeycomb retinal dystrophy, offered by DNA Labs UAE, is a genetic screening aimed at detecting mutations in the EFEMP1 gene, which is associated with this specific form of retinal dystrophy. Doyne honeycomb retinal dystrophy, also known as Malattia Leventinese, is an inherited eye disorder characterized by the accumulation of drusen (yellow deposits) beneath the retina, leading to progressive vision loss. The test is crucial for individuals with a family history of the condition or those experiencing symptoms, providing valuable insights into their genetic predisposition.
Performed at DNA Labs UAE, a facility known for its advanced genetic testing capabilities, the EFEMP1 gene test involves collecting a DNA sample, typically through a blood draw or cheek swab. The laboratory then analyzes the sample to identify any mutations in the EFEMP1 gene that could indicate the presence of or risk for developing Doyne honeycomb retinal dystrophy.
The cost of the test is 4400 AED, reflecting the comprehensive analysis and the specialized technology employed in detecting the genetic markers associated with the condition. For patients and families, the results from this test can guide clinical decisions, including early intervention and management strategies, to preserve vision and improve quality of life. It also offers the chance for affected families to understand their risk of passing the condition onto future generations, aiding in informed family planning decisions.
